吉西他滨联合卡培他滨治疗蒽环类和紫杉类耐药的转移性乳腺癌

目的：观察吉西他滨（Gemcitabine）联合卡培他滨（Capecitabine）治疗蒽环类和紫杉类药物耐药的转移性乳腺癌患者的近期疗效和不良反应。方法：40例患者采用吉西他滨联合卡培他滨方案化疗：吉西他滨1000mg/m2静脉滴注,第1、8天;卡培他滨1000mg/m2口服,每日两次,第1-14天;21天为1周期。每2周期评价疗效,每周期进行毒性和安全性评估。结果：40例患者共接受156周期化疗,中位化疗周期4个（2-6个周期）,总有效率（overall remission rate,RR）为35.00%（14/40）,其中临床完全缓解率（clinical completeremission,cCR）为7.50%（3/40）,部分缓解率（partial remission,PR）为27.50%（11/40）,稳定率（stable dis-ease,SD）为30.00%（12/40）,进展率（progressive disease,PD）为35.00%（14/40）。结论：吉西他滨联合卡培他滨是治疗蒽环类和紫杉类药物耐药的转移性乳腺癌的有效方案,其血液学和非血液学毒性耐受性良好。

The effect of Gemcitabine combined Capecitabine regimens for anthracycline-and taxane-refractory metastatic breast cancer

Objective：To evaluate the clinical effect and toxicity of Gemcitabine combined with Capecitabine regimens for anthracycline-and taxane-refractory metastatic breast cancer.Methods： All 40 patients with anthracycline-and taxane-refractory metastatic breast cancer were treated with regimen： Gemcitabine was given at a dose of 1000mg/m2 on day1 and day 8,Capecitabine was given at a dose of 1000mg/m2,twice daily,on day 1-14,21 days was one cycle.Response rate was evaluated every two cycles and toxicity was evaluated every cycle.Results： All 40 patients received 156 cycles,overall remission rate（RR） was 35.00%（14/40）,clinical complete remission rate（cCR） was 7.50%（3/40）,partial remission rate（PR） was 27.50%（11/40）,stable disease rate（SD） was 30.00%（12/40）,progressive disease rate（PD） was 35.00%（14/40）.Conclusion： Combination of Gemcitabine with Capecitabine regimen is an effective method to treat anthracycline-and taxane-refractory metastatic breast cancer with tolerable toxicity.